Menu

Flu Vaccine-Narcolepsy Link Explained?

A new study sheds light on why those who received GlaxoSmithKline’s flu vaccine were at an increased risk of developing the sleep disorder.

Dec 20, 2013
Jef Akst

WIKIMEDIA, PEDRO SIMOESEditor’s note (August 1, 2014): This paper was retracted after the authors failed to reproduce the results.

People suffering from narcolepsy may be victims of their own immune system, according to a study published this week (December 18) in Science Translational Medicine. Specifically, researchers have found evidence to suggest that the sleep disorder might result from an immune reaction against the wakefulness-regulating hormone hypocretin—possibly one triggered GlaxoSmithKline’s Pandemrix flu vaccine that has been linked to an increased risk of developing narcolepsy, or even a case of the flu itself.

The work reveals “the fingerprints of an immune attack,” neuroimmunologist Lawrence Steinman of Stanford University in Palo Alto, California, who was not involved in the research, told ScienceNOW.

The results are “exactly what we’ve been waiting for,” added vaccine expert Hanna Nohynek of the National Institute for Health and Welfare in Helsinki, who helped identify the link between Pandemrix and narcolepsy.

In 2009, narcolepsy researcher Emmanuel Mignot of Stanford University and colleagues, funded in part by a GSK grant, discovered a curious link between the sleep disorder and immunity: nearly all narcolepsy patients have a particular type of human leukocyte antigen (HLA), molecules that present antigens to T cells to help the immune system distinguish self from non-self. Working in an immune cell line with the narcolepsy-associated HLA, Mignot and his colleagues tested the effects of hypocretin on T cells from either from one of four narcolepsy patients or from their identical twins that didn’t suffer from the disorder. For each set of twins, the researchers found that the T cells from the affected individual reacted to pieces of hypocretin that were displayed by the HLAs; T cells from the unaffected twin did not react.

The researchers also tested the T cells of 10 Irish children who had developed the sleep disorder following the administration of the Pandemrix vaccine, along with those from healthy siblings who were also vaccinated and carried the same HLA type. Once again, only the T cells taken from the narcolepsy patients reacted to the hypocretin epitopes.

Mignot’s team also tested the effects of the H1N1 virus hemagglutinin protein, which resembles hypocretin epitopes, and found that fragments of the viral protein also elicited an immune reaction. The findings suggest that narcolepsy could result from the immune system reacting to native molecules as a result of their similar structure to pathogenic proteins.

“[This] is the first mechanistic explanation of the disease,” vaccine expert Steven Black of Cincinnati Children’s Hospital Medical Center in Ohio told ScienceNOW. Of course, he added, “there’s plenty of work to do” to fully understand what leads to the onset of narcolepsy.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.